

Supplemental Tables for:
Outcomes of breast cancer patients treated with chemotherapy, biologic therapy, endocrine therapy, or active surveillance during the COVID-19 pandemic
Faisal Fa'ak et al.

Chemotherapy	Frequency
Paclitaxel	94
Capecitabine	41
CMF	30
TCHP	29
TCb	27
AC-T	23
AC	19
Doxorubicin	19
Carboplatin	11
TC	11

Supplementary Table 1. Most frequently administered chemotherapy regimens. CMF, Cyclophosphamide, Methotrexate, 5-Fluorouracil. TCHP, Docetaxel, Carboplatin, Trastuzumab, Pertuzumab. TCb, Paclitaxel, Carboplatin. AC-T, Doxorubicin, Cyclophosphamide, Paclitaxel. AC, Doxorubicin, Cyclophosphamide. TC, Docetaxel, Cyclophosphamide.

Age	Sex	Treatment	Cause of Death	Stage	Location	CCI	BMI
58	F	Not on treatment	COVID-19	Stage III	Long Island	3	45
67	F	T-DM1	COVID-19	Metastatic Disease	Manhattan	11	30
69	F	AC	COVID-19	Stage III	Manhattan	2	37
70	F	Halaven	COVID-19	Metastatic Disease	Manhattan	8	31
70	F	Not on treatment	COVID-19	Metastatic Disease	Manhattan	8	31
75	F	TCHP	COVID-19	Stage II	Manhattan	3	25
77	F	Not on treatment	COVID-19	Stage I	Manhattan	3	24
79	F	CMF	COVID-19	Stage III	Manhattan	9	50
83	F	Faslodex, T-DM1	COVID-19	Metastatic Disease	Brooklyn	8	34
85	F	Not on treatment	COVID-19	Stage I	Long Island	6	25

Supplemental Table 2. **Demographic details from patients' who expired following SARS-CoV-2 infection.**